NovoCure's TTFields Therapy Shows Promising Results in Phase 3 Trial

Saturday, 30 March 2024, 10:34

Novocure's recent phase 3 trial results for its TTFields therapy demonstrate a significant improvement in time to intracranial progression, potentially impacting medical practices. Despite some mixed secondary endpoints, the study reveals a positive outlook for NovoCure's treatment for brain metastases from non-small-cell lung cancer. With the stock seeing a rebound after facing challenges in other trials, investors are now considering the potential of NovoCure in the healthcare sector.
https://store.livarava.com/18164f1d-ee82-11ee-8911-87cc5c87fb08.jpg
NovoCure's TTFields Therapy Shows Promising Results in Phase 3 Trial

A 'potentially practice changing' therapy

In a press release Wednesday, Novocure announced that its phase 3 METIS clinical trial met its primary endpoint by demonstrating a statistically significant improvement in time to intracranial progression for patients.

Major benefit and potential practice change

Patients receiving TTFields therapy showed a median time to intracranial progression of 21.9 months compared to 11.3 months for those on supportive care alone.

What's next for Novocure investors?

Preliminary analysis of secondary endpoints like overall survival showed no statistical significance, but positive trends were noted in quality of life and progression.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe